Association between plasma Alzheimer’s disease markers and MRI markers of cerebral small vessel disease and neurodegeneration: the SMART‐MR Study

Biomarkers for Alzheimer’s disease (AD), including amyloid‐beta (Abeta) and phosphorylated‐tau have recently been accurately detected in blood. Non‐specific biomarkers such as neurofilament light (NFL) and glial fibrillary acidic protein (GFAP) have been added as complementary biomarkers to fully investigate AD etiology in vivo. This has increased the possibility to examine relationships with other pathways to AD, such as white matter hyperintensities (WMH) and brain atrophy on MRI. Our aim was to explore the relationship between plasma AD biomarkers and MRI markers of cerebral small vessel disease and neurodegeneration in mid‐ and late life.